Physician profile
Andrew Michael Mount
NPI 1912351495
$1,126.55
in general payments reported to CMS, 2019-2025
16 companies · $38.38 in 2025
The $38.38 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.69 · 2022: $100 · 2023: $312 · 2024: $582 · 2025: $38.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Education: $13.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.39 |
| Education | $13.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.97 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.32 | 2024 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $169.81 | 2022-2024 | Dupixent |
| Pacira Pharmaceuticals Incorporated | $141.29 | 2021-2023 | Iovera, Exparel |
| Bard Peripheral Vascular, INC. | $60.29 | 2024-2025 | Powerport M.R.I. Implantable Port |
| Boston Scientific Corporation | $54.66 | 2022 | |
| Aimmune Therapeutics, INC. | $46.26 | 2024 | |
| Pylant Medical | $29.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.93 | 2023 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $15.94 | 2024 | Andexxa |
| Amgen INC. | $14.80 | 2023 | Avsola |
| Curonix LLC | $13.87 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Celltrion USA INC. | $13.46 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $13.42 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.32 | 2024 | Rebyota |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8.21 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.